• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Treat NMD Logo (Copyright)

TREAT-NMD

Advancing diagnosis, care and treatment for people with neuromuscular diseases around the world

Contact us

header-right

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
  • What We Do
    • Advisory Committee for Therapeutics
    • The Global Registry Network
    • Core Datasets
    • Education
    • Post-Marketing Surveillance
  • Resources and Support
    • Neuromuscular Disease Information
    • Research Overview
    • Standards of Care & Family Guides
    • SOP Library
    • Social and Ethical Issues
  • Conference
    • Registration
    • Sponsorship Opportunities
    • Conference Programme
    • Sponsors of the TREAT-NMD 8th International Conference
    • Programme Committee
    • Abstracts
    • Venue
  • News & Events
    • News
    • TREAT-NMD Events
    • All Events
    • Submit an Event
    • Newsletter Sign-up
    • Contact Us

TREAT-NMD Achieves ISO 27001:2022 Accreditation for Information Security Management System

Home / TREAT-NMD News / TREAT-NMD Achieves ISO 27001:2022 Accreditation for Information Security Management System
TREAT-NMD Achieves ISO27001:2022 Accreditation

TREAT-NMD Achieves ISO 27001:2022 Accreditation for Information Security Management System

 

We are thrilled to announce that TREAT-NMD has achieved the prestigious ISO 27001:2022 accreditation for our Information Security Management System (ISMS). This milestone underscores our unwavering dedication to ensuring the secure and safe management of all information and systems entrusted to us.

What is ISO 27001:2022?

ISO 27001:2022 is globally recognised as the foremost standard for Information Security Management Systems (ISMS). It sets forth requirements that an ISMS must fulfil and provides guidance for organisations of any size and industry sector in establishing, implementing, maintaining, and continually improving their information security management practices.

Why it matters.

In today’s landscape, where cyber threats loom large and evolve rapidly, managing information security risks is paramount. ISO 27001:2022 equips us with a framework to become proactive in identifying and addressing vulnerabilities. By adhering to this standard, we are demonstrating our commitment to adopting best practices and principles for safeguarding data.

What it means for TREAT-NMD, and more importantly, for you

Our commitment to ensuring the highest standards of information security not only ensure we are aligned with legislation, but also help us to:

  1. Mitigate Security Risks – Our ISMS not only keeps information secure but also enhances our resilience against potential threats. Its flexibility ensures adaptation to evolving risks, bolstering our defence mechanisms.
  2. Improve Our Company Culture – By establishing a robust ISMS, we are educating our team about the significance of data security. This fosters a culture of vigilance and responsibility, empowering our employees to safeguard our valuable assets.
  3. Protect Our Data – Confidentiality, availability, and integrity of data is paramount to us. Our ISMS implementation introduces robust policies and procedures, alongside physical and technical controls, to uphold the sanctity of our data assets.
  4. Centralise Our Data Management – Centralising our information streamlines oversight and management processes. This ensures comprehensive control over our data landscape, promoting efficiency and informed decision-making.

Looking ahead

Achieving ISO 27001:2022 accreditation signifies a significant milestone in our commitment to information security excellence. As we continue to prioritise the safety and integrity of our data, we remain steadfast in our pursuit of operational excellence and unwavering support for the rare neuromuscular disorder community.

Stay tuned for further information governance updates as we embark on our journey of continual improvement and innovation.

24 April 2024

Primary Sidebar

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
  • What We Do
    • Advisory Committee for Therapeutics
      • Members of the Advisory Committee for Therapeutics
      • Take Part in TACT
      • Past Applicants
    • The Global Registry Network
      • Members of the Registry Network
    • Core Datasets
      • DM dataset
      • DMD dataset
      • FSHD dataset
      • LGMD
      • SMA
    • Education
      • Masterclasses and Events
      • Digital Resources
      • Endorsement of External Programmes
    • Post-Marketing Surveillance
  • Resources and Support
    • Neuromuscular Disease Information
      • Becker muscular dystrophy
      • Charcot-Marie-Tooth
      • Congenital muscular dystrophy
      • Congenital myasthenic syndromes
      • Duchenne muscular dystrophy
      • Facioscapulohumeral muscular dystrophy
      • GNE myopathy
      • Limb girdle muscular dystrophy
      • Myotonic dystrophy
      • Myotubular and centronuclear myopathies
      • Spinal muscular atrophy
    • Research Overview
      • DMD
        • Gene Therapy for DMD
        • Mutation Specific Approaches
        • Cell Therapy
        • Drug Therapy
    • Standards of Care & Family Guides
      • CM Care
      • CMD Care
      • DM Care
      • DMD Care
      • BMD Care
      • FSHD Care
      • SMA Care
    • SOP Library
      • MDX Mouse (DMD)
      • GRMD Dog (DMD)
      • CMD Mouse (CMD)
      • SMA Mouse (SMA)
      • CMD animal models
      • MDC1A Preclinical Research
      • Cell Lines
        • Clinical Outcome Measures
        • Functional Evaluation Tools
        • NMR (MRI/MRS) Imaging
        • Muscle Biopsy
    • Social and Ethical Issues
  • Conference
    • Registration
    • Sponsorship Opportunities
    • Conference Programme
    • Sponsors of the TREAT-NMD 8th International Conference
    • Programme Committee
    • Abstracts
    • Venue
  • News & Events
    • News
    • TREAT-NMD Events
    • All Events
    • Submit an Event
    • Newsletter Sign-up
    • Contact Us

Footer

Contact us

4th Floor
The Catalyst
Newcastle upon Tyne
NE4 5TG
United Kingdom
info@treat-nmd.com

Links

Home
Who we are
What we do
Who we support
Resources & support
Connect with us
Privacy Policy
Cookies

Newsletter Sign Up

Sign up to our monthly newsletter

 
ISO 27001 Accreditation Logo

Connect

info@treat-nmd.com
TREAT NMD © 2025
Privacy Policy
Sitemap
STCS LTD

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
  • What We Do
    • Advisory Committee for Therapeutics
      • Members of the Advisory Committee for Therapeutics
      • Take Part in TACT
      • Past Applicants
    • The Global Registry Network
      • Members of the Registry Network
    • Core Datasets
      • DM dataset
      • DMD dataset
      • FSHD dataset
      • LGMD
      • SMA
    • Education
      • Masterclasses and Events
      • Digital Resources
      • Endorsement of External Programmes
    • Post-Marketing Surveillance
  • Resources and Support
    • Neuromuscular Disease Information
      • Becker muscular dystrophy
      • Charcot-Marie-Tooth
      • Congenital muscular dystrophy
      • Congenital myasthenic syndromes
      • Duchenne muscular dystrophy
      • Facioscapulohumeral muscular dystrophy
      • GNE myopathy
      • Limb girdle muscular dystrophy
      • Myotonic dystrophy
      • Myotubular and centronuclear myopathies
      • Spinal muscular atrophy
    • Research Overview
      • DMD
        • Gene Therapy for DMD
        • Mutation Specific Approaches
        • Cell Therapy
        • Drug Therapy
    • Standards of Care & Family Guides
      • CM Care
      • CMD Care
      • DM Care
      • DMD Care
      • BMD Care
      • FSHD Care
      • SMA Care
    • SOP Library
      • MDX Mouse (DMD)
      • GRMD Dog (DMD)
      • CMD Mouse (CMD)
      • SMA Mouse (SMA)
      • CMD animal models
      • MDC1A Preclinical Research
      • Cell Lines
        • Clinical Outcome Measures
        • Functional Evaluation Tools
        • NMR (MRI/MRS) Imaging
        • Muscle Biopsy
    • Social and Ethical Issues
  • Conference
    • Registration
    • Sponsorship Opportunities
    • Conference Programme
    • Sponsors of the TREAT-NMD 8th International Conference
    • Programme Committee
    • Abstracts
    • Venue
  • News & Events
    • News
    • TREAT-NMD Events
    • All Events
    • Submit an Event
    • Newsletter Sign-up
    • Contact Us